Trials / Unknown
UnknownNCT04355026
Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- General and Teaching Hospital Celje · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
In the current situation it is of great importance to discover a safe, cost-effective and available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent studies have shown that hydroxychloroquine could have a role in the treatment of infected patients. It is however not very likely that hydroxychloroquine alone could be adequate for treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and hydroxychloroquine in Covid-19 patients. Hypothesis 1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease in hospitalized Covid-19 patients compared to hydroxychloroquine alone. 2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of secundary pulmonary infections in hospitalized Covid-19 patients compared to hydroxychloroquine alone. 3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bromhexine Oral Tablet and/or hydroxychloroquine tablet | bromhexine 16 mg TID hydroxychloroquine 200 mg BID |
Timeline
- Start date
- 2020-04-10
- Primary completion
- 2020-06-30
- Completion
- 2020-07-31
- First posted
- 2020-04-21
- Last updated
- 2020-04-21
Locations
1 site across 1 country: Slovenia
Source: ClinicalTrials.gov record NCT04355026. Inclusion in this directory is not an endorsement.